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Abstract 31 
Background: Brain amyloid-b (Ab) peptide  is released into the interstitial fluid (ISF) in a neuronal 32 
activity-dependent manner, and Ab deposition in Alzheimer’s disease (AD) is linked to baseline 33 
neuronal activity. Although the intrinsic mechanism for Ab generation remains to be elucidated, 34 
interleukin-like epithelial-mesenchymal transition inducer (ILEI) is a candidate for an endogenous Ab 35 
suppressor. 36 
Objective: This study aimed to access the mechanism underlying ILEI secretion and its effect on Ab 37 
production in the brain. 38 
Methods: ILEI and Ab levels in the cerebral cortex were monitored using a newly developed ILEI-39 
specific ELISA and in vivo microdialysis in mutant human Ab precursor protein-knockin mice. ILEI 40 
levels in autopsied brains and cerebrospinal fluid (CSF) were measured using ELISA. 41 
Results: Extracellular release of ILEI and Aβ was dependent on neuronal activation and specifically on 42 
tetanus toxin-sensitive exocytosis of synaptic vesicles. However, simultaneous monitoring of 43 
extracellular ILEI and Aβ revealed that a spontaneous fluctuation of ILEI levels appeared to inversely 44 
mirror that of Aβ levels. Selective activation and inhibition of synaptic receptors differentially altered 45 
these levels. The evoked activation of AMPA-type receptors resulted in opposing changes to ILEI and 46 
Aβ levels. Brain ILEI levels were selectively decreased in AD. CSF ILEI concentration correlated with 47 
that of Aβ, and were reduced in AD and mild cognitive impairment. 48 
 4 
Conclusion: ILEI and Aβ are released from distinct subpopulations of synaptic terminals in an activity-49 
dependent manner, and ILEI negatively regulates Ab production in specific synapse types. CSF ILEI 50 
might represent a surrogate marker for the accumulation of brain Ab. 51 
 52 
Keywords: Alzheimer's disease, Aβ, ILEI, Synapse, Neurotransmitter receptor 53 
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INTRODUCTION 55 
      Family with sequence similarity 3, member C (FAM3C) is a ubiquitously expressed, multi-56 
functional secretory protein. It is upregulated by transforming growth factor b signaling and causes 57 
epithelial-mesenchymal transition of epithelial cells and hepatocytes; thus, FAM3C has also been named 58 
interleukin-like epithelial-mesenchymal transition inducer (ILEI) [1-5]. Other emerging functions of 59 
FAM3C/ILEI include inhibition of osteoblast differentiation and mineralization through Runx2 60 
downregulation in the bone marrow [6, 7], and gluconeogenesis suppression via induction of heat shock 61 
factor 1, and activation of the phosphoinositide 3-kinase and Akt pathway in the liver [8, 9]. 62 
      In previous studies, we found that extracellularly released ILEI interacts with the g-secretase 63 
complex to suppress production of amyloid-b (Ab) peptides [10]. Ab  is generated through b- and g-64 
secretase-mediated proteolytic processing of Ab precursor protein (AbPP) and is released into the 65 
interstitial fluid (ISF) of brain parenchyma in a neuronal activity-dependent manner [11, 12]. Excessive 66 
accumulation of aggregated Ab in the cerebral cortex and hippocampus is considered to initiate the 67 
pathogenic cascade of Alzheimer’s disease (AD). Recent imaging studies revealed that Ab deposition in 68 
the brain is tightly linked to baseline neuronal activity, and that component regions of the default mode 69 
network are the sites most vulnerable to Ab deposition [13, 14]. ILEI reduces Ab production by 70 
facilitating lysosome/proteasome-mediated turnover of the C-terminal fragments of AbPP while sparing 71 
g-secretase activity. During AD pathogenesis, the expression of ILEI is significantly reduced in the brain 72 
and inversely correlated with accumulated Ab levels [10, 15]. These findings suggest that reduced 73 
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expression of brain ILEI is an antecedent event that prompts the inevitable Ab pathology observed in 74 
AD. 75 
      We previously reported that ILEI colocalizes with AbPP and g-secretase complex components 76 
at the presynaptic terminals [15]. However, two questions remain unanswered: (1) how is ILEI released 77 
into the ISF and (2) is there a relationship between extracellularly released ILEI and Ab levels? In this 78 
study, we developed a sandwich ELISA for ILEI that enabled quantitative analysis of expression and 79 
secretion of ILEI in the mouse brain. Using in vivo microdialysis, we found that ILEI was released into 80 
the ISF in a neuronal activity-dependent manner, much like Ab. Moreover, activation or inhibition of 81 
specific neurotransmitter receptors led to distinct changes in the extracellular levels of ILEI and Ab in 82 
the cerebral cortex. 83 
 84 
MATERIALS AND METHODS 85 
Preparation of monoclonal antibodies against ILEI 86 
To generate monoclonal antibodies against ILEI protein, two BDF1 mice were immunized with a 87 
recombinant His-tagged, secreted form of human ILEI (25-227 amino acid residues, #ATGP1251, 88 
ATGen Co. Ltd., Gyeonggi-do, Korea). After preparation of the lymph nodes and spleens, cells were 89 
fused with the myeloma cell line P3-X63-Ag8. The hybridoma supernatants of mixed clones were 90 
screened by ELISA. Among 95 clones that recognized the immunogen, three monoclonal antibody 91 
clones showed the highest immunoreactivity after the second round of subcloning by limiting dilution. 92 
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Finally, two clones, namely 24C1 and 42C1, were selected by ELISA against recombinant mouse ILEI 93 
(R&D Systems Inc., Minneapolis, MN, Cat# 2868-FM). Both monoclonal antibodies were purified by 94 
protein A affinity chromatography from 1 L of each hybridoma cell culture supernatant. In addition, the 95 
antibody mAb24C1 was conjugated to horseradish peroxidase according to the manufacturer’s 96 
instructions (Dojindo, Kumamoto, Japan, Cat# LK11).  97 
 98 
Development of a sandwich ELISA for ILEI 99 
First, 96-well flat-bottom ELISA plates (Nunc, Thermo Fisher Scientific, Rochester, NY, Cat# 469914) 100 
were coated with mAb42C1 (144 ng/well in 100 μL/well of 0.2 M sodium carbonate–bicarbonate buffer, 101 
pH 9.4). The plates were incubated at 4°C overnight and then washed three times with 300 μL/well of 102 
PBS (pH 7.2) with 0.1% Tween 20. Nonspecific binding sites were blocked by incubation with a 103 
blocking reagent (IS-CD-500E; Cosmo Bio. Co, Ltd., Tokyo, Japan, Cat# IS-CD-500E) for 1 h at 37°C. 104 
    The standards were prepared with a solution of recombinant mouse ILEI (2868-FM; R&D 105 
system, Inc., Cat# 2868-FM) or human ILEI (15678-H08H-50, Sino Biological Inc., Beijing, China, 106 
Cat# 15678-H08H-50) in a dilution buffer (Immuno-Biological Laboratories Co, Ltd., Gunma, Japan, 107 
Cat# 27769D100). Standards of 0.313, 0.625, 1.25, 2.5, 5.0, and 10.0 ng/mL were prepared immediately 108 
before loading. Unknown samples were prepared in an appropriate dilution with dilution buffer. Wells 109 
were each loaded with 100 μL of the designated solution. The plates were subsequently incubated for 18 110 
h at 4°C without shaking before being washed five times. 111 
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    The plates were then incubated with the detection antibody solution, which contained 112 
horseradish-peroxidase-conjugated antibody mAb24C1 at 50 ng/well in 100 μL/well of a dilution buffer 113 
(Immuno Shot 2; Cosmo Bio, Cat# IS-002) for 1 h at 4°C. They were then washed five times, incubated 114 
for another hour at room temperature, and again washed five times. Subsequently, the plates were 115 
developed for 30 min with 100 μL/well of a 3,3’,5,5’-tetramethylbenzidine dihydrochloride substrate 116 
solution (ImmunoPure Turbo TMB; Pierce Chemical Co., Rockford, IL, Cat# 5120). The reaction was 117 
stopped by adding 100 μL/well of 1 M sulfuric acid (Nacalai Tesque, Kyoto, Japan, Cat# 95626-06). 118 
Finally, the plates were read at a wavelength of 450 nm (Benchmark Plus; Bio-Rad Laboratories Inc., 119 
Hercules, CA, USA). 120 
 121 
Immunoblotting 122 
ILEI-knockout HEK293 cells [15] were transfected with expression plasmids using linear 123 
polyethylenimine (Polysciences Inc., Warrington, PA, Cat# 23966). Cell lysates were sonicated on ice 124 
and centrifuged at 4°C and 15,000 rpm for 25 min. Per lane, 15–20 μg of proteins were separated by 125 
12% SDS-PAGE and transferred to a polyvinylidene fluoride membrane (Merck Millipore, Co., 126 
Billerica, MA, Cat# IPVH00010). These membranes were incubated with the primary antibodies at 4°C 127 
overnight before being washed and incubated with corresponding horseradish peroxidase-conjugated 128 
secondary antibodies (1:5,000, Merck Millipore, Cat# AP308P) for 1 h. This process was followed by 129 
enhanced chemiluminescence detection (Nacalai Tesque, Cat# 07880-70). Blots were scanned using a 130 
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LAS-4000 imaging system (Fujifilm, Tokyo, Japan). The primary antibodies used were as follows: 131 
mAb42C1 (1:2,000), mAb24C1 (1:2,000), anti-GAPDH antibody (1:2,000, Merck Millipore, Cat# 132 
MAB2549), and anti-V5 antibody (1:2,000, Nacalai Tesque, Cat# 04434-94).  133 
 134 
Animals 135 
Four month-old male C57BL/6J mice (CLEA Japan, Inc., Tokyo, Japan) and humanized mutant AbPP-136 
knockin mice (AppNL-G-F mice [16]) were used in this study. Mice were maintained at room temperature 137 
(25°C) under a standard 12:12 h light:dark cycle, with food and water available ad libitum. AppNL-G-F 138 
mice were intraperitoneally injected with a mixture of anesthetics (Domitor, ZENOAQ, Fukushima, 139 
Japan; Vetorphale, Meiji Seika Pharma Co., Ltd., Tokyo, Japan; midazolam, Sando Co., Ltd., Tokyo, 140 
Japan) and then with an anti-anesthetic (Antisedan, ZENOAQ, Fukushima, Japan). Tetanus toxin (Sigma, 141 
St. Louis, MO, Cat# T3194) was also intraperitoneally administered. All experimental procedures were 142 
approved by the Institutional Animal Care and Use Committee of the Shiga University of Medical 143 
Science (Approval ID: 2018-12-1), and experiments were performed according to the Guide for the Care 144 
and Use of Laboratory Animals. 145 
 146 
Measurement of ILEI and Ab in the mouse brain 147 
Mice were euthanized by cervical dislocation, and whole brains and cerebrospinal fluid (CSF) were 148 
obtained. Whole forebrains were homogenized using a motor-driven Teflon/glass homogenizer (10 149 
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strokes) in four volumes of Tris-buffered saline (50 mM Tris, pH 7.6, 150 mM NaCl, and 0.5 mM 150 
EDTA) that contained a protease inhibitor cocktail. The homogenates were then centrifuged at 100,000 151 
g for 20 min on a TLA 100.4 rotor in a TLX ultracentrifuge (Beckman, Palo Alto, CA, USA). The 152 
supernatants were taken as the soluble fractions and subjected to a protein assay (BioRad, Cat# 500-153 
0116JA) and sandwich ELISAs specific for ILEI, mouse/rat Ab40 (Immuno-Biological Laboratories, 154 
Cat# 27720), or human total Ab (Immuno-Biological Laboratories, Cat# 27729). Brain lysates were 155 
obtained by adding NP40 and CHAPSO to homogenates at 1% of each final concentration.  156 
 157 
In vivo microdialysis 158 
Microdialysis was performed as previously described by Takeda et al. [17]. Briefly, guide cannulas (8 159 
mm in length) were stereotactically implanted into the right cerebral cortex (bregma 1.9 mm, 0.5 mm 160 
lateral to the midline, and 0.8 mm ventral to skull surface) of anesthetized mice, and then bonded in place 161 
with dental cement. Accordingly, the inserted dialysis probe was located in the medial prefrontal cortex 162 
spanning the anterior cingulate, prelimbic, and infralimbic areas, which are AD-vulnerable regions. At 163 
least two days after guide cannula implantation, a microdialysis probe with a 2 mm-long polyethylene 164 
membrane (1,000 kDa molecular weight cutoff, PEP-4-02, Eicom, Kyoto, Japan, Cat# 600132) was 165 
inserted through the guide, and the mouse was placed in a transparent acrylic cage (250 × 250 × 350 166 
(height) mm). The probe was connected to peristaltic and microsyringe pumps with fluorinated ethylene 167 
propylene tubing (250 μm in diameter): the syringe pump pushed and the peristaltic pump pulled a 168 
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dialysis buffer (119 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl2, and 0.15% bovine serum albumin; filtered 169 
through a 0.22-μm-pore-sized membrane) at a synchronous flow rate. After preperfusion with a dialysis 170 
buffer at a flow rate of 10 μL/min for 2 h, dialyzed samples were collected into polypropylene tubes 171 
every 1 or 2 h using a fraction collector (EFC-96, Eicom). During sampling, flow rate was kept constant 172 
at 0.5 μL/min. Sampling began at 16:00, and the mice were allowed to move freely in the cage while 173 
sampling occurred. The concentrations of ILEI and Ab were measured using the ELISAs described 174 
above. Basal levels of ILEI or Ab were defined as the mean concentration from four samples obtained 175 
before reverse dialysis. All values for each mouse were then normalized as percentages of the basal level 176 
for each point. 177 
 178 
Assessment of mouse locomotor activity 179 
To assess mouse locomotor activity during microdialysis, we used the Scanet MV-40 system (Melquest, 180 
Toyama, Japan). Vertical and horizontal movements of mice were tracked and measured every 60 min 181 
for 2 days using digital counters with infrared sensors, which were crosswise distributed at 6-mm 182 
intervals and a height of 30 mm above the floor of a transparent acrylic cage (250 × 250 mm). The 183 
moving distances of mice every hour were expressed in arbitrary units.  184 
 185 
Reverse microdialysis 186 
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The following compounds were used for reverse microdialysis: tetrodotoxin (Fujifilm Wako, Tokyo, 187 
Japan, Cat# 206-11071), AMPA (Abcam, Cambridge, UK, Cat# ab12005), NBQX disodium salt 188 
(Abcam, Cat# ab144489), NMDA (Nacalai Tesque, Cat# 22034-16), D-AP5 (Abcam, Cat# ab120003), 189 
diazepam (Fujifilm Wako, Cat# 045-18901), picrotoxin (Sigma Chemicals, Cat# P1675), (R, S)-190 
Baclofen (Abcam, Cat# ab120149), CGP55845 hydrochloride (Sigma Chemicals, Cat# SML0594), 191 
nicotine (Nacalai Tesque, Cat# 24332-62), D-tubocurarine chloride (Nacalai Tesque, Cat# 35637-84), 192 
pilocarpine hydrochloride (Nacalai Tesque, Cat# 28008-31), and atropine sulfate (Nacalai Tesque, Cat# 193 
03533-11). For reverse microdialysis, compounds were diluted at the indicated concentration in Ringer’s 194 
solution. 195 
 196 
Autopsied human brain tissues 197 
Frozen brain tissues from the temporal cortex of 15 deceased patients with AD, 15 age-matched non-198 
neurological disease control subjects, and 10 non-AD neurological disease control subjects were 199 
obtained from the Brain Bank for Aging Research, Tokyo Metropolitan Institute of Gerontology (Tokyo, 200 
Japan). All study subjects or their next of kin provided written informed consent for brain donation, and 201 
experimental procedures were approved by the Shiga University of Medical Science Review Board 202 
(Approval ID: 28-096). All patients with AD fulfilled the National Institute of Neurological and 203 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Associations criteria 204 
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for probable AD. Soluble fractions of temporal cortex homogenates were prepared as previously 205 
described (10). 206 
 207 
Clinical CSF samples 208 
CSF was analyzed in control subjects (mean age 76.88 years, n = 25), MCI subjects (mean age 71.24 209 
years, n = 25), and patients with AD (mean age 75.84 years, n = 25). Written informed consent was 210 
obtained from each participant before lumbar puncture for CSF collection. CSF analysis was approved 211 
by the Ethics Committees of Niigata University (Approval ID: 2015-2427). CSF concentrations of Aβ38, 212 
Aβ40, and Aβ42 were analyzed using V-PLEX Aβ Peptide Panel 1 (6E10) (Meso Scale Discovery, 213 
Rockville, MD) with MESO QuickPlex SQ 120 (Meso Scale Diagnostics). Intra- and interassay 214 
coefficients of variation were <20% for all assays. The ILEI measurement of CSF samples was approved 215 
by the Ethics Committees of Shiga University of Medical Science (Approval ID: 27-210). 216 
 217 
Statistical analysis 218 
Statistical analyses involved two-tailed unpaired Student’s t-tests or one-way ANOVA combined with 219 
Dunnett’s test for multiple comparisons. Correlation analyses were performed using the Spearman's rank 220 
correlation test. StatPlus:mac LE software (AnalystSoft, Vancouver, Canada) was used for statistical 221 





Monoclonal antibodies 24C1 and 42C1 recognize distinct epitopes of ILEI protein 226 
      We generated monoclonal antibodies against ILEI by immunizing BDF1 mice with 227 
recombinant His-tagged, human ILEI that was purified from conditioned medium of ILEI-228 
overexpressing HEK293 cells. Based on immunoblotting of HEK293 cell lysate and ELISA against 229 
recombinant ILEI, we selected the clones 24C1 and 42C1. The monoclonal antibodies mAb24C1 and 230 
mAb42C1 recognized both human and mouse ILEI proteins according to immunoblotting and ELISA.  231 
      To define each epitope of these antibodies, we first generated expression vectors for human 232 
ILEI mutants harboring deletion or truncation of amino acid residues 25–99 (D25–99), 100–154 (D100–233 
154), 155–190 (D155–190), or 191–227 (D191–227) (Fig. 1A). Immunoblotting of mutant ILEI-234 
transfected HEK293 cell lysates revealed that mAb24C1 failed to label ILEI-D155–190, whereas 235 
mAb42C1 did not react with ILEI-D191–227 (Fig. 1B). We also prepared several missense ILEI mutants 236 
harboring alanine substitutions of evolutionally conserved amino acid residues: G103A, G169A, D151A, 237 
R179A, W212A, C58A, C64A, C86A, and C221A. Immunoblotting revealed that mAb24C1 and 238 
mAb42C1 selectively lacked immunoreactivity to G169A-ILEI and W212A-ILEI, respectively (Fig. 239 
1C). According to a previous report on crystal structure [18], Gly169 and Trp212 are surface-exposed and 240 
distant from each other in their respective locations (Fig. 1D). These results suggest that mAb24C1 and 241 
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mAb42C1 recognize distinct epitopes of ILEI, to which the residues Gly169 and Trp212 are critical, 242 
respectively. 243 
  244 
Development and validation of the ILEI-specific ELISA 245 
      In our sandwich ELISA that was specific for ILEI, mAb42C1 was suitable as a capture antibody 246 
and horseradish peroxidase-labeled mAb24C1 was useful as a detection antibody. The optimized 247 
concentrations of the capture and detection antibodies were 1.44 and 0.50 μg/mL, respectively. The 248 
performance of this ELISA for recombinant mouse and human ILEI are shown in Fig. 1E. The standard 249 
curves were based on six serial dilutions of mouse or human recombinant ILEI and were linear over 250 
0.31–10.0 ng/mL. The detection limit (3.3 s/a, where s = SD of the blank; a = slope of the standard curve) 251 
and the quantification limit (10 s/a), which were based on eight independent determinations of a blank 252 
in standard solutions, were 0.04 and 0.11 ng/mL for mouse ILEI, respectively, and 0.05 and 0.16 ng/mL 253 
for human ILEI, respectively.  254 
      For validation of the assay at different dilutions, we used soluble fractions of mouse brain 255 
homogenates diluted at 1:10. Dilutional parallelism was determined by evaluating each sample at its 256 
initial strength (1:10) and at dilutions of 1:2, 1:4, and 1:8. Observed-to-expected ratios for the dilutional 257 
parallelism of each sample of the full-strength solution ranged from 85% to 136%. Spiking recovery was 258 
determined by adding 0.0, 1.25, 2.50, and 5.00 ng/mL of recombinant ILEI to mouse brain homogenate 259 
samples. Observed-to-expected ratios for spiking recovery of the homogenate diluted at 1:40 ranged 260 
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from 88% to 89%. The intra-assay coefficient of variation for soluble fractions of brain homogenates 261 
was <10%. 262 
 A study reported homodimerization of ILEI via intermolecular disulfide bonds [18]. According 263 
to the predicted conformation of dimerized ILEI [18], mAb42C1 recognized the opposite side of the 264 
binding interface, whereas the recognition site of mAb24C1 may be occluded by the binding interface. 265 
Both antibodies detected a single band corresponding to monomer ILEI in mouse brain lysates under 266 
reducing or nonreducing conditions (Fig. 1F). The nonreduced ILEI monomer migrated faster in SDS-267 
PAGE than the disulfide-reduced ILEI monomer (Fig. 1F), which can be explained by the formation of 268 
intramolecular disulfide bonds [18]. This indicated that no detectable level of ILEI homodimer was 269 
present in the mouse brain, at least using these antibodies. 270 
 271 
Expression and secretion of ILEI in the mouse forebrain  272 
      We collected brains and CSF every 3 h for 24 h from C57BL/6J mice housed under a 12:12 h 273 
light:dark cycle and then measured ILEI levels using the established ELISA. To examine expression 274 
levels of brain ILEI, we prepared NP40- and CHAPSO-solubilized lysates of forebrains. ILEI 275 
concentrations of forebrain lysates were within a relatively narrow range during day/night cycles (Fig. 276 
2A). To assess secretion of ILEI, we used the supernatant from ultracentrifuged forebrain homogenates. 277 
The ILEI concentrations of the soluble fractions changed periodically (Fig. 2B); thus, the extracellular 278 
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release of ILEI apparently fluctuated over time. The levels of CSF ILEI also fluctuated but were not 279 
synchronized with levels of ILEI in the soluble brain fractions (Fig. 2C). 280 
 Furthermore, we measured Ab concentrations in these same samples. Ab levels showed 281 
fluctuations that were more prominent in the soluble fractions than in the lysates and were not associated 282 
with the fluctuations of ILEI levels (Fig. 2D, E). However, Ab  fluctuation was roughly parallel to ILEI 283 
fluctuation in the CSF (Fig. 2F). 284 
 285 
Monitoring of cortical ISF ILEI and Ab by in vivo microdialysis 286 
     We used in vivo microdialysis to monitor ISF ILEI and Ab in the cerebral cortex of conscious, 287 
freely-moving AppNL-G-F knockin (KI) mice (3–4-months old), in which the humanized mutant AbPP is 288 
expressed under its endogenous promoter [16]. Dialysates were collected every hour and mouse 289 
movement was tracked. Levels of ISF ILEI periodically fluctuated and higher levels were weakly 290 
associated with higher locomotor activity (Fig. 3A, B). Intraperitoneally injected anesthetics suppressed 291 
ILEI  levels in the dialysates; however, these levels were restored by treatment with an anti-anesthetic 292 
(Fig. 3C). Anesthetic treatment also decreased Ab levels with kinetics that were similar to ILEI levels 293 
(Fig. 3D). Although ISF Ab levels have previously been reported to fluctuate over time [19], we found 294 
that ISF ILEI levels tended to inversely fluctuate relative to the fluctuating levels of Ab  (Fig. 3E, F). 295 
 296 
Activity-dependent release of ILEI and Ab 297 
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      Using reverse microdialysis, we tested pharmacological modulation of synaptic activity. 298 
Preliminary reverse microdialysis of bromophenol blue solution in the frontal cortex resulted in its focal 299 
diffusion within the restricted area even after continuous perfusion for 48 h (Fig. 4A). Perfusion with 300 
tetrodotoxin, a voltage-dependent sodium channel blocker, suppressed ILEI levels in a dose-dependent 301 
manner (Fig. 4B). A similar decrease in ISF Ab levels was reported in a previous report [12]. 302 
Intraperitoneal administration of tetanus toxin, an inhibitor of synaptic vesicle exocytosis, decreased 303 
ILEI and Ab levels in the dialysates (Fig. 4C), indicating that the release of ILEI and Ab into the ISF is 304 
associated with synaptic vesicle exocytosis. Levels of ISF ILEI decreased by >95% after tetanus toxin 305 
treatment, suggesting that ISF ILEI was predominantly derived from synaptic vesicles. Furthermore, 306 
given that the rates of ILEI and Aβ showed similar declines after tetanus toxin treatment, the half-life of 307 
ISF ILEI was apparently equivalent to that of Aβ, which has previously been reported to be as short as 308 
~2 h [20]. 309 
 310 
Activation and inhibition of glutamatergic receptors 311 
      Our finding that ISF levels of ILEI and Ab were similarly associated with neuronal activity but 312 
inversely fluctuated in untreated mice seemed paradoxical. To address this issue, we examined how 313 
evoked activation or basal activity inhibition of distinct neurotransmitter receptors affected ISF ILEI and 314 
Aβ levels. Hettinger et al. [21] reported that reverse dialysis of AMPA and NBQX, an agonist and 315 
antagonist of AMPA-type receptors, respectively, gradually decreased ISF Aβ levels in the hippocampus 316 
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of mutant AbPP- and mutant Presenilin-1-double transgenic (APPswe/PS1DE9) mice. We observed 317 
similar effects of AMPA and NBQX on ISF Aβ levels following cortical microdialysis in AppNL-G-F mice 318 
(Fig. 5A, B). Specifically, NBQX decreased ISF ILEI levels, whereas AMPA increased ISF ILEI levels 319 
from 20 h after reverse dialysis began (Fig. 5A, B). An important characteristic of AMPA receptors is 320 
rapid desensitization; in a previous study, perfusion of 1 μM and 100 μM AMPA into the rat 321 
hippocampus increased and decreased the 5-HT level in dialysates, respectively [22]. Similarly, we 322 
tested perfusions of 1, 20, and 100 μM AMPA and found that ILEI levels increased in a dose-dependent 323 
manner (Fig. 5C); this suggests that desensitization of AMPA receptors did not affect ILEI release. 324 
Hettinger et al. (2018) reported a similar result for Aβ release [21]. 325 
      Treatment with higher doses of NMDA reduced ISF Ab in the neocortex of AppNL-G-F mice 326 
whereas treatment with D-AP5, an NMDA receptor antagonist, markedly increased ISF Ab levels (Fig. 327 
5D), consistent with previous findings from hippocampal microdialysis of APPswe/PS1DE9 transgenic 328 
mice [23]. Similarly, NMDA reduced ISF ILEI levels; however, D-AP5 treatment led to a delayed 329 
decrease in ILEI levels (Fig. 5E). 330 
 331 
Activation and inhibition of GABAergic receptors 332 
       Microdialysis perfusion of diazepam and baclofen, agonists of GABAA and GABAB receptors, 333 
respectively, suppressed ISF ILEI and Ab levels, whereas perfusion of the antagonists of these receptors 334 
led to a marked increase in both ILEI and Ab levels (Fig. 6). These results are consistent with the 335 
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sustained stimulation of GABAergic receptors suppressing overall cortical neuronal activity. It must be 336 
noted, however, that the decrease in ISF ILEI levels after diazepam treatment was rapid and reached 337 
>90% at its peak, while ISF Ab levels decreased to <50% of the baseline. These findings suggest that 338 
ILEI may be released directly from GABAA receptor-expressing neurons at their depolarization. During 339 
the perfusion, we did not observe any obvious changes in mouse behavior or awake-sleep cycles. 340 
 341 
Activation and inhibition of cholinergic receptors 342 
      Perfusion of nicotine and tubocurarine, an agonist and antagonist of nicotinic acetylcholine 343 
(ACh) receptors, respectively, increased ISF Ab levels (Fig. 7A, B). Although nicotine treatment did not 344 
alter the average levels of ISF ILEI, it did result in a higher amplitude and more regular cycle of periodic 345 
fluctuations in these levels: the amplitude was approximately 50% that of the baseline level over a ~12 346 
h cycle (Fig. 7A). Tubocurarine treatment did not have any clear effect on ISF ILEI in the acute phase 347 
but increased ILEI levels >24 h after perfusion began (Fig. 7B). Perfusion of pilocarpine and atropine, 348 
an agonist and antagonist for muscarinic ACh receptors, respectively, decreased and increased ISF Aβ 349 
levels, respectively (Fig. 7C, D), consistent with previous findings [24, 25]. Similarly, pilocarpine 350 
decreased ILEI levels; however, atropine did not affect ILEI levels (Fig. 7C, D).  351 
 352 
Reduced expression of ILEI in AD brains 353 
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 Using semi-quantitative immunoblotting, we previously showed that ILEI expression levels 354 
decreased in autopsy brains of AD patients compared with those of non-demented controls and non-AD 355 
disease controls, including brains of patients with corticobasal degeneration, progressive supranuclear 356 
palsy, amyotrophic lateral sclerosis, Parkinson’s disease, and dementia with Lewy bodies [10]. To 357 
measure ILEI levels in autopsied brains, we validated our ELISA method with a soluble fraction of 358 
human brains as previously described. The limits of detection and quantification were 0.24 and 0.74 359 
ng/mL, respectively. The observed-to-expected ratios of the dilutional parallelism and spiking recovery 360 
were in the ranges of 94%–99%, and 72%–99%, respectively. The intra-assay coefficient of variation 361 
was <10%. Using ELISA, we examined ILEI levels in the same set of autopsied brains according to our 362 
previous report [10], and confirmed a significant and selective decrease in ILEI levels in AD brains (Fig. 363 
8A). Furthermore, we measured ILEI concentrations in CSF samples of clinical subjects and found that 364 
CSF ILEI levels correlated with those of Aβ40 and Aβ42 and were lower in AD and MCI patients than in 365 
control patients (Fig. 8B, C). 366 
 367 
DISCUSSION 368 
      We quantitatively examined the extracellular release of ILEI protein in the medial prefrontal 369 
cortex of the mouse brain while also comparing ILEI levels with those of Aβ peptides. We found that 370 
ISF ILEI levels exhibited circadian fluctuation, which was similar to reports on Aβ. Our results suggested 371 
that extracellular release of these proteins was associated with neuronal activity and largely depended on 372 
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tetanus toxin-sensitive exocytosis of the synaptic vesicle and the circadian fluctuation of ILEI and Aβ 373 
was loosely linked to mouse locomotor activity. In addition, we revealed a superimposed fluctuation in 374 
which ILEI and Aβ levels were inversely altered. Perfusion of agonists or antagonists for glutamate, 375 
GABA, and ACh receptors differentially altered ISF ILEI and Aβ levels, indicating that these proteins 376 
are released from distinct subpopulations of presynaptic terminals. Declines in ISF ILEI and Aβ levels 377 
followed inhibited depolarization of AMPA, GABAA, or GABAB receptor-expressing neurons, which 378 
suggests that the normal activities of these receptors directly or indirectly sustain ISF ILEI and Aβ levels 379 
in vivo. 380 
      The cerebral cortex predominantly consists of two types of neurons: (1) glutamatergic 381 
projection neurons reciprocally connected to the thalamus and to each other, and (2) mainly local circuit 382 
GABAergic neurons [26]. The basal forebrain cholinergic system innervates the neocortex to act as a 383 
slow modulator that increases the excitability of neuronal networks [27]. In the present study, reverse 384 
microdialysis in the cerebral cortex resulted in focal diffusion of compounds even after prolonged 385 
perfusion, and infusion of agonists or antagonists was presumed to modulate activation of the target 386 
receptor-expressing neurons near the dialysis probe. Output synapses of the local circuit neurons are 387 
located near the dialysis probe, whereas axon terminals of the projection neurons are far from the probe 388 
but involved in the reciprocal networks. ILEI and Aβ are known to be released predominantly from 389 
presynaptic terminals [28, 29]. Hence, prolonged perfusion of receptor modulators would likely have 390 
both direct and indirect effects on the ISF ILEI and Aβ levels around the probe. Such indirect effects are 391 
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predicted to be mediated by the inter-regional network connections in which the probe-inserted site is 392 
involved. Nevertheless, reverse microdialysis with receptor modulators in the cerebral cortex resulted in 393 
similar effects on ISF Aβ levels as those previously reported in the hippocampus [21, 23]. 394 
      AMPA receptors are expressed on the major population of synapses that mediate fast excitatory 395 
transmission in the cerebral cortex. Among the receptor modulator treatments tested in this study, AMPA 396 
treatment was unique in producing opposing effects on ISF ILEI and Aβ levels: an increase in ILEI and 397 
a decrease in Aβ. The paradoxical finding that the levels of ILEI and Ab in the ISF are similarly 398 
associated with neuronal activity but fluctuate inversely can possibly be explained by a transition in the 399 
dominancy of AMPA receptor-mediated synaptic activation. On the other hand, continuous stimulation 400 
of nicotinic ACh receptors enhanced the spontaneous fluctuation of ISF ILEI levels: nicotine treatment 401 
resulted in a higher amplitude and more regular cycle of periodic fluctuations in ILEI levels. Nicotinic 402 
cholinergic stimulation is known to potentiate glutamatergic transmission [30] and is required for the 403 
generation of synchronized ultraslow fluctuation of neuronal activity in the prefrontal cortex [31]. 404 
However, the underlying mechanism of these effects could not be addressed in the present study and it 405 
will therefore require further investigation in future research. 406 
      Recently, Rice et al. [32] reported that the distribution of AbPP is prominent in GABAergic 407 
interneurons in the hippocampus, and they showed that 98% of AbPP-positive cells in the CA1 region 408 
are GABAB receptor subunit 1-positive. In the present study, treatment with agonists of GABAA or 409 
GABAB receptors reduced ISF Aβ levels whereas treatment with antagonists of these receptors 410 
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remarkably increased ISF Aβ levels. While our results seem to be discordant with the findings of [32], it 411 
is currently unclear whether this discrepancy is due to differences between the hippocampus and cerebral 412 
cortex or between direct and indirect effects. 413 
      Cholinergic receptors are expressed at only 3% of the total number of nerve terminals in the rat 414 
hippocampus, and AbPP is then colocalized at approximately 3%–4% of cholinergic terminals [33]. 415 
Nevertheless, in our study, prolonged perfusion of agonists or antagonists of these receptors led to 416 
marked changes in cortical ISF levels of ILEI and Aβ. For example, nicotine perfusion unexpectedly 417 
enhanced ISF Aβ levels in the cerebral neocortex. Chronic nicotine treatment has been shown to reduce 418 
Aβ deposition in the brain of AbPP-transgenic (Tg2576) mice [34]. These findings suggest the 419 
possibility that nicotine could produce unidentified effects on Aβ degradation or aggregation. Indeed, 420 
cotinine, a stable metabolite of nicotine, can inhibit Aβ oligomerization and fibrillation [35]. 421 
      The results of this study are consistent with those of previous studies showing that ILEI and 422 
AbPP are constituents of the release-competent pool of synaptic vesicles [15, 36]. Although the 423 
modulatory activities of released Aβ on synaptic transmission have been reported (reviewed by [37]), 424 
the physiological functions of ILEI at the synaptic terminal remain to be clarified. Barthet, et al. [38] 425 
reported that inhibiting γ-secretase cleavage of synaptic AbPP impairs the replenishment of release-426 
competent synaptic vesicles, thus, extracellular ILEI might modify these functions of Aβ and AbPP. 427 
      In contrast to ISF levels of ILEI and Ab, CSF levels of these proteins were roughly paralleled 428 
in mouse and clinical samples. The difference in these fluctuations between ISF and CSF may be 429 
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attributable to differences in fluid volume between ISF and CSF or in turnover dynamics between ILEI 430 
and Ab. Our finding that CSF ILEI levels were significantly lower in AD and MCI patients than in 431 
control patients suggests that CSF ILEI might be a surrogate marker for brain Ab accumulation or AD 432 
development. To more accurately evaluate Ab and ILEI levels in clinical samples, it will however be 433 
necessary to carefully assess the condition of patients before and during CSF sampling. 434 
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FIGURE LEGENDS 558 
Figure 1 559 
Characterization of mAb24C1, mAb42C1, and sandwich ELISA for ILEI. A) Scheme of the ILEI 560 
construct and deletion mutants. The predicted conformation model of ILEI protein contains nine b-sheets 561 
(b) and three a-helices (a). SS: signal sequence; V5: V5 tag. B) Lysates of HEK293 cells (lane 1) or 562 
ILEI-knockout HEK293 cells transiently transfected with mock, V5-tagged wild-type, or various ILEI 563 
deletion mutants (lanes 2–7) were subjected to SDS-PAGE. Blots were probed with anti-V5 antibody, 564 
mAb24C1, or mAb42C1. C) Immunoblotting using lysates of ILEI-knockout HEK293 cells transiently 565 
transfected with mock, V5-tagged wild-type, or various missense mutant ILEI constructs. Blots were 566 
probed with anti-V5, mAb24C1, mAb42C1, or anti-GAPDH antibodies. D) Gly169 and Trp212 are distant 567 
from each other on the ILEI structure: Gly169 is located in the loop between the 2nd and 3rd a-helices, 568 
whereas Trp212 is located in the loop between the 8th and 9th b-sheets. E) Representative standard curves 569 
from ELISA for human and mouse ILEI proteins. F) Immunoblotting of mouse brain lysate samples 570 
with no reducing agent (nonreducing), 5% 2-mercaptoethanol (2ME), or 75 mM dithiothreitol (DTT). 571 
Blots were probed using mAb24C1 or mAb42C1. 572 
 573 
Figure 2 574 
Extracellular levels of ILEI periodically fluctuate in the mouse brain. Brains and cerebrospinal fluid 575 
(CSF) were obtained every 3 h from C57BL/6J mice that were housed under a 12:12 h light:dark cycle. 576 
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CSF samples from three mice at each time point were combined. ILEI levels in brain lysates (A), the 577 
soluble fractions of brains (B), and CSF (C) were measured using ELISA. Ab levels in brain lysates (D), 578 
the soluble fractions of brains (E), and CSF (F) were also measured using mouse Ab40-specific ELISA. 579 
Values are shown as means ± SEMs (n = 3). 580 
 581 
Figure 3 582 
ISF ILEI levels are positively correlated with locomotor activity but inversely associated with ISF Ab 583 
levels. A) Cerebrocortical ILEI levels were monitored using in vivo microdialysis in a C57BL/6J mouse; 584 
the movement distance of these mice was also recorded (distances moved per hour are expressed in 585 
arbitrary units). A representative result is shown. B) Graph showing the correlation between ISF ILEI 586 
levels and movement distance (n = 144, r = 0.460). C) Mice were intraperitoneally injected with 587 
anesthetics and then with anti-anesthetic during monitoring of ISF ILEI. Values are shown as means ± 588 
SEMs from three independent experiments. D) Cerebrocortical ISF levels of ILEI and Ab were measured 589 
after intraperitoneal injection with anesthetics. Values shown represent means ± SEM from three 590 
independent experiments. All values for each mouse were normalized as percentages of the basal level, 591 
which was defined as the mean concentration from samples obtained before injection (C, D). E) Cortical 592 
ISF levels of ILEI and Ab were simultaneously monitored via in vivo microdialysis in AppNL-G-F mice 593 
for 2 days. A representative result is shown. F) Reverse correlation between ISF ILEI and Ab levels (n 594 
= 112, r = 0.423). 595 
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 596 
Figure 4 597 
ILEI is released into the ISF in a synaptic activity-dependent manner. A) Reverse microdialysis of 598 
bromophenol blue for 48 h resulted in local diffusion in the frontal cortex of mice. The arrow indicates 599 
the position of the microdialysis probe. B) Reverse microdialysis with tetrodotoxin (TTX) reduced the 600 
cortical ISF ILEI levels of AppNL-G-F mice in a dose-dependent manner. C) Intraperitoneal administration 601 
of tetanus toxin decreased ISF levels of ILEI and Ab in dialysates. Values are shown as means ± SEMs 602 
from three independent experiments. All values for each mouse were normalized as percentages of the 603 
basal level, which was defined as the mean concentration from samples obtained before reverse dialysis 604 
or treatment. 605 
 606 
Figure 5 607 
Extracellular ILEI and Ab levels were differentially altered by treatment with agonists or antagonists of 608 
AMPA and NMDA receptors. Indicated doses of AMPA (A), NBQX (B), AMPA (C), NMDA (D), and 609 
D-AP5 (E) were administered through reverse microdialysis to the frontal cortex of AppNL-G-F mice. The 610 
graphs show relative levels of extracellular ILEI (closed diamonds) and Ab (open diamonds). All values 611 
for each mouse were normalized as percentages of the basal level, which was defined as the mean 612 
concentration from samples obtained before reverse dialysis. 613 
 614 
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Figure 6 615 
Activation of GABAA or GABAB receptors reduced extracellular ILEI and Ab levels. Indicated doses 616 
of diazepam (A), picrotoxin (B), baclofen (C), and CGP55845 (D) were administered through reverse 617 
microdialysis to the frontal cortex of AppNL-G-F mice. The graphs show relative levels of extracellular 618 
ILEI (closed diamonds) and Ab (open diamonds). Values are shown as means ± SEMs from three 619 
independent experiments. All values for each mouse were normalized as percentages of the basal level, 620 
which was defined as the mean concentration from samples obtained before reverse dialysis. 621 
 622 
Figure 7 623 
Extracellular ILEI and Ab levels were differentially altered by treatment with agonists or antagonists of 624 
nicotinic and muscarinic ACh receptors. Indicated doses of nicotine (A), tubocurarine (B), pilocarpine 625 
(C), and atropine (D) were administered through reverse microdialysis to the frontal cortex of AppNL-G-F 626 
mice. The graphs show relative levels of extracellular ILEI (closed diamonds) and Ab (open diamonds). 627 
Values are shown as means ± SEMs from three independent experiments. All values for each mouse 628 
were normalized as percentages of the basal level, which was defined as the mean concentration from 629 
samples obtained before reverse dialysis. 630 
 631 
Figure 8 632 
 36 
Reduced expression of ILEI in the AD brain. A) ILEI levels in soluble fractions from temporal cortex 633 
homogenates from AD brains (n = 15), age-matched non-neurological disease controls (n = 15), and 634 
non-AD neurological disease controls (n = 10) were measured using ELISA. Non-AD disease controls 635 
included corticobasal degeneration (2 cases), progressive supranuclear palsy (2 cases), amyotrophic 636 
lateral sclerosis (2 cases), Parkinson’s disease (2 cases), and dementia with Lewy bodies (2 cases). Lines 637 
and error bars represent means ± SEM. Statistical analysis was performed using Dunnett’s multiple 638 
comparison test. Significant differences relative to the ratio in controls are indicated (mean ± SE, 639 
*p < 0.05). B) ILEI concentrations in CSF from AD patients (n = 25), MCI patients (n = 25), and age-640 
matched non-neurological disease controls (n = 25) were measured using ELISA. Lines and error bars 641 
represent means ± SEM. Statistical analysis was performed using Dunnett’s multiple comparison test. 642 
Significant differences relative to the ratio in controls are indicated (mean ± SE, **p < 0.01). C) CSF 643 
ILEI concentrations were correlated with those of Aβ40 (n = 75, r = 0.678) and Aβ42 (n = 75, r = 0.627). 644 
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